Delta-Fly Pharmaの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/05/09 | 1,177 | 1,192 | 1,150 | 1,159 | -16 | -1.4% | 272,900 |
2023/05/08 | 1,149 | 1,191 | 1,148 | 1,175 | +34 | +3% | 281,200 |
2023/05/02 | 1,150 | 1,158 | 1,132 | 1,141 | -8 | -0.7% | 208,900 |
2023/05/01 | 1,161 | 1,181 | 1,143 | 1,149 | -39 | -3.3% | 317,500 |
2023/04/28 | 1,183 | 1,206 | 1,157 | 1,188 | +13 | +1.1% | 269,200 |
2023/04/27 | 1,167 | 1,197 | 1,147 | 1,175 | +2 | +0.2% | 330,800 |
2023/04/26 | 1,206 | 1,212 | 1,153 | 1,173 | -48 | -3.9% | 466,900 |
2023/04/25 | 1,242 | 1,263 | 1,212 | 1,221 | -34 | -2.7% | 379,000 |
2023/04/24 | 1,287 | 1,322 | 1,238 | 1,255 | -60 | -4.6% | 580,700 |
2023/04/21 | 1,320 | 1,335 | 1,268 | 1,315 | -2 | -0.2% | 480,300 |
2023/04/20 | 1,368 | 1,384 | 1,314 | 1,317 | -28 | -2.1% | 336,900 |
2023/04/19 | 1,391 | 1,391 | 1,342 | 1,345 | -66 | -4.7% | 441,400 |
2023/04/18 | 1,398 | 1,458 | 1,392 | 1,411 | -17 | -1.2% | 434,400 |
2023/04/17 | 1,490 | 1,533 | 1,413 | 1,428 | -47 | -3.2% | 701,800 |
2023/04/14 | 1,510 | 1,545 | 1,457 | 1,475 | +3 | +0.2% | 683,800 |
2023/04/13 | 1,435 | 1,500 | 1,412 | 1,472 | +36 | +2.5% | 672,600 |
2023/04/12 | 1,369 | 1,443 | 1,359 | 1,436 | +37 | +2.6% | 565,600 |
2023/04/11 | 1,308 | 1,399 | 1,303 | 1,399 | +94 | +7.2% | 831,800 |
2023/04/10 | 1,320 | 1,398 | 1,297 | 1,305 | +4 | +0.3% | 1,143,100 |
2023/04/07 | 1,360 | 1,432 | 1,295 | 1,301 | -49 | -3.6% | 1,713,600 |
2023/04/06 | 1,441 | 1,461 | 1,322 | 1,350 | -127 | -8.6% | 2,112,700 |
2023/04/05 | 1,306 | 1,560 | 1,305 | 1,477 | +156 | +11.8% | 7,468,400 |
2023/04/04 | 1,500 | 1,538 | 1,259 | 1,321 | -9 | -0.7% | 4,986,200 |
2023/04/03 | 1,330 | 1,330 | 1,330 | 1,330 | +300 | +29.1% | 33,900 |
2023/03/31 | 1,041 | 1,058 | 1,026 | 1,030 | -16 | -1.5% | 256,900 |
2023/03/30 | 1,045 | 1,072 | 1,030 | 1,046 | +11 | +1.1% | 425,400 |
2023/03/29 | 1,063 | 1,076 | 1,024 | 1,035 | -53 | -4.9% | 592,700 |
2023/03/28 | 1,113 | 1,127 | 1,074 | 1,088 | -12 | -1.1% | 506,100 |
2023/03/27 | 1,204 | 1,220 | 1,094 | 1,100 | -164 | -13% | 1,225,400 |
2023/03/24 | 1,227 | 1,280 | 1,197 | 1,264 | +42 | +3.4% | 573,400 |
2023/03/23 | 1,211 | 1,240 | 1,181 | 1,222 | +7 | +0.6% | 466,200 |
2023/03/22 | 1,304 | 1,310 | 1,200 | 1,215 | -72 | -5.6% | 771,400 |
2023/03/20 | 1,339 | 1,345 | 1,275 | 1,287 | -58 | -4.3% | 536,600 |
2023/03/17 | 1,293 | 1,358 | 1,275 | 1,345 | +73 | +5.7% | 847,000 |
2023/03/16 | 1,212 | 1,282 | 1,190 | 1,272 | +34 | +2.7% | 805,900 |
2023/03/15 | 1,215 | 1,262 | 1,176 | 1,238 | +63 | +5.4% | 1,009,200 |
2023/03/14 | 1,278 | 1,324 | 1,165 | 1,175 | -103 | -8.1% | 1,294,800 |
2023/03/13 | 1,305 | 1,328 | 1,231 | 1,278 | -98 | -7.1% | 1,457,700 |
2023/03/10 | 1,271 | 1,400 | 1,256 | 1,376 | +104 | +8.2% | 2,239,100 |
2023/03/09 | 1,251 | 1,430 | 1,225 | 1,272 | +9 | +0.7% | 3,987,500 |
2023/03/08 | 1,324 | 1,360 | 1,230 | 1,263 | -91 | -6.7% | 1,742,800 |
2023/03/07 | 1,314 | 1,358 | 1,276 | 1,354 | +67 | +5.2% | 1,089,200 |
2023/03/06 | 1,373 | 1,378 | 1,257 | 1,287 | -144 | -10.1% | 2,047,100 |
2023/03/03 | 1,246 | 1,450 | 1,218 | 1,431 | +194 | +15.7% | 2,248,100 |
2023/03/02 | 1,328 | 1,369 | 1,170 | 1,237 | -49 | -3.8% | 2,827,700 |
2023/03/01 | 1,446 | 1,510 | 1,286 | 1,286 | -179 | -12.2% | 2,657,500 |
2023/02/28 | 1,391 | 1,504 | 1,375 | 1,465 | +84 | +6.1% | 4,041,700 |
2023/02/27 | 1,200 | 1,432 | 1,184 | 1,381 | +229 | +19.9% | 5,418,300 |
2023/02/24 | 1,107 | 1,152 | 1,096 | 1,152 | +27 | +2.4% | 264,700 |
2023/02/22 | 1,152 | 1,165 | 1,114 | 1,125 | -49 | -4.2% | 530,200 |
501~
550
件表示中 / 1611件
類似銘柄と比較する
現在ご覧いただいている「DELTA-P」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
DELTA-P | 57,200円 | - | - | 0.00% | - | 20.24倍 |
|
創薬ベンチャー。既存の抗がん物質を組み合わせて安全性と有効性を高めた抗がん剤を開発 |
モダリス | 7,600円 | - | - | 0.00% | - | 1.62倍 |
|
遺伝子治療薬の創薬ベンチャー、DNA切断しないエピゲノム編集に強み。研究開発中心は米国 |
カイノス | 123,600円 | +3.7% | +2.7% | 2.59% | 8.68倍 | 0.77倍 |
|
臨床検査薬の中堅メーカー。生化学、免疫血清学的検査用試薬に重点。共同開発の促進に注力 |
カルナバイオ | 28,100円 | +13.5% | - | 0.00% | - | 2.17倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
DWTI | 11,300円 | -15.1% | - | 0.00% | - | 7.06倍 |
|
三重大学発創薬ベンチャー。プロテインキナーゼ阻害剤開発技術はじめ眼病治療薬開発に集中 |
市場注目の銘柄
チャート関連のコラム